Hao‐Wei Wang

National Institutes of Health — United States

Medicine · Health Sciences

34h-index4.8kcitations153works4.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(34), Lymphoma Diagnosis and Treatment(31), Chronic Lymphocytic Leukemia Research(26), Viral-associated cancers and disorders(22), Immune Cell Function and Interaction(12)

Publications151 total

Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia
Blood Advances·2025Open Access
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study
Blood·2025
Global, regional, and national burden of pediatric intracerebral hemorrhage from 1990 to 2021: a systematic analysis for the global burden of disease study 2021
Annals of Medicine·2025Open Access
Gene expression profiling reveals two overarching types of ALCL with distinct targetable biology: an LLMPP study
Blood·2025
Phase 2 trial of cladribine plus immediate rituximab for 1st-line treatment of hairy cell leukemia – long term follow-up of original and additional patient cohorts
Blood·2025Open Access
MAP2K1 and MAP2K2 genes alterations in hairy cell leukemia and hairy cell leukemia variant.
Blood·2025Open Access
CD19/22 CAR T-cells in children and young adults with B-ALL: Final Phase 1 trial results
Blood·2025
Phase 2 trial of encorafenib plus binimetinib for patients with BRAF V600 mutated relapsed/refractory hairy cell leukemia
Blood·2025Open Access
Harmonization on defining B‐cell recovery post CD19‐CAR T‐cell therapy in B‐cell acute lymphoblastic leukemia: An international consensus statement
HemaSphere·2025Open Access
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia
Blood·2025· 1 citedOpen Access
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies
Cytotherapy·2025Open Access
Primary Results from a Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Characteristics and outcomes of Kaposi sarcoma herpesvirus–associated inflammatory cytokine syndrome
Blood Advances·2025· 4 citedOpen Access
Molecular analysis of bilateral T-cell vitreoretinal lymphoma
npj Precision Oncology·2025Open Access
Predictors and outcomes associated with prolonged hospital length of stay in intracerebral hemorrhage: a multicenter prospective cohort study in China
BMC Medicine·2025· 1 citedOpen Access
Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy
JCO Precision Oncology·2025Open Access
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies
2025· 1 citedOpen Access
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies
Nature Communications·2025· 7 citedOpen Access
Abstract 4820: Anti-CD72 nanobody-based CAR-T affinity maturation leads to improved in vitro efficacy versus low antigen density lymphoma models, but limited benefit in vivo
Cancer Research·2025
High-throughput screening of process parameters and composition in laser additive manufacturing via in-situ X-ray imaging
Scripta Materialia·2025· 3 cited
page 1 of 8Next →

Frequent Co-authors

Constance M. Yuan(14), Maryalice Stetler‐Stevenson(11), Nirali N. Shah(10), Haneen Shalabi(10), Bonnie Yates(9), Seth M. Steinberg(9), Terry J. Fry(8), Elaine S. Jaffe(7), Alina Dulau‐Florea(6), Stefania Pittaluga(6), Irina Marić(6), Johanna A. Joyce(5), Steven L. Highfill(5), David F. Stroncek(5), Mei Yang(5), Katherine R. Calvo(5), Pamela L. Wolters(4), Lauren Little(4), Hongbin Yuan(4), Mark Raffeld(4)